Pseudomonas aeruginosa Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in specific pathogen detection, quantification, or developing targeted anti-infective strategies against multi-drug resistant strains? Our P. aeruginosa P1 Specific Neutra™ Antibody Products help you accelerate discovery, obtain high-quality immunoassay results, and develop highly specific diagnostic tools through advanced recombinant antibody engineering techniques targeting a critical cell-surface virulence factor.
Contact our team to get an inquiry now!
Introduction of P. aeruginosa
P. aeruginosa is a motile, Gram-negative, opportunistic bacterium recognized globally as a critical public health threat due to its intrinsic and acquired resistance to multiple antibiotics, placing it on the list of ESKAPE pathogens. It is a leading cause of nosocomial infections, particularly devastating in immunocompromised patients, burn victims, and individuals suffering from chronic respiratory conditions like Cystic Fibrosis.
A major determinant of P. aeruginosa virulence and host-pathogen interaction is its Lipopolysaccharide (LPS), an integral component of the outer membrane. Structurally, LPS is composed of three parts: Lipid A (the endotoxin), the core oligosaccharide, and the O-antigen (O-polysaccharide, also known as O-specific antigen or OSA). The O-antigen is highly variable among strains and forms the basis of the International Antigen Typing Scheme (IATS). The P1 antigen is derived from this crucial surface architecture, likely representing a highly immunogenic and specific epitope within the O-antigen, which dictates serotype specificity and is essential for the bacterium's survival and interaction with the host immune system. Targeting this surface structure is a validated strategy for both detection and therapeutic intervention.
Fig.1 P. aeruginosa pathogenesis.1
Antibodies Against P. aeruginosa
Antibodies targeting specific cell-surface components of P. aeruginosa are indispensable tools in microbiology. The Creative Biolabs' P. aeruginosa Specific Neutra™ Antibody Products offer high specificity, providing a powerful instrument for several critical applications:
- Direct Quantification: Robustly validated for quantitative ELISA, these antibodies accurately measure the bacterial load in diverse research matrices, including biological fluids, surpassing the limitations of culture-based methods.
- Opsonophagocytic Activity (OPA) Studies: As a surface-exposed component, antibodies are ideal for evaluating opsonophagocytic killing. The Neutra™ feature suggests these antibodies can facilitate host immune response and pathogen clearance, a key metric for vaccine or passive immunity candidates.
- Cross-Reactivity and Specificity Analysis: Due to targeted specificity, these antibodies enable precise mapping of cross-reactivity profiles against other P. aeruginosa serotypes or related Gram-negative species, ensuring the high specificity required for diagnostic and therapeutic product development.
- Characterization and Isolation: The high affinity of our antibodies makes them suitable for Western Blotting and Immunoprecipitation to isolate and characterize the P1-containing LPS structure, furthering the understanding of its structural variations and interaction partners on the bacterial surface.
Why Choose Us?
Creative Biolabs' two decades of experience and commitment ensure our P. aeruginosa Specific Neutra™ Antibody Products offer distinct advantages over generic reagents:
- Targeted Neutralization (Neutra™): Antibodies are validated for binding and the potential to block key bacterial functions, providing a critical tool for pre-clinical therapeutic research.
- Unparalleled Specificity and Selectivity: Rigorous testing confirms minimal cross-reactivity with non-P1 serotypes or commensal flora, ensuring highly accurate and interpretable assay results.
- Exceptional Consistency: A standardized production workflow guarantees high performance across every batch, minimizing experimental variability.
- Comprehensive Support: We provide detailed functional data, Published Data, and direct access to our 20+ years of specialist knowledge to assist with assay design and troubleshooting.
FAQs
Q: Is the antibody compatible with high-throughput screening (HTS)?
A: Yes, these stable, high-affinity monoclonal antibodies are engineered for automated ELISA and HTS platforms, ensuring rapid, consistent data for large-scale screening campaigns.
Q: Are special precautions needed for biological fluids?
A: Yes. Detecting P1 in complex biological fluids (e.g., sputum, serum) may require sample pre-treatment (e.g., lysis or heat-inactivation) for optimal antigen accessibility and to minimize non-specific matrix effects.
Q: How does this antibody compare to traditional chemical detection methods?
A: Antibody detection offers superior functional specificity and sub-nanomolar sensitivity, detecting the antigen at lower, biologically relevant concentrations in its native conformation, unlike methods relying solely on chemical structure.
Q: Can the Neutra™ antibody be used for therapeutic screening?
A: Absolutely. The neutralizing capability makes this product highly suitable for in vitro and ex vivo functional assays aimed at measuring the inhibition of bacterial adhesion, invasion, or toxin activity.
Creative Biolabs is dedicated to providing the definitive solutions for complex microbiology challenges. Our P. aeruginosa Specific Neutra™ Antibody Products represent the intersection of advanced antibody engineering and critical pathogen research, offering the specificity, reliability, and functional potential required to move your anti-infective or diagnostic project forward.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Qin, Shugang et al. "Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics." Signal transduction and targeted therapy vol. 7,1 199. 25 Jun. 2022, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41392-022-01056-1
